RxDoctor Payments Data

Jeffrey Tomaszewski, MD

Urology · Camden, NJNPI 1710166244

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Boston Scientific at 41.9% of the total.

$3,066in general payments, 2019–2025

Across 52 payments — averaging $58.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Calyxo, Inc.$263
  • Intuitive Surgical$249
  • Dentsply IH AB$226
  • Neotract Inc.$195
  • Medtronic$150
  • plus $697 from 13 others
$341,225in research payments, 2019–2025

Across 19 payments — averaging $17,959 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$340K
  • Bayer$1K

What the payments were for

  • Food & beverage$3,066100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,066 in reported general payments places this provider in the 60th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$132,407
Medicare patients
311
Services billed
749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron51$26,544
Tamsulosin Hcl221$2,815
Solifenacin Succinate40$1,608
Oxybutynin Chloride75$840
Finasteride64$605
Oxybutynin Chloride ErOxybutynin Chloride19$344
Insulin SyringeSyringe And Needle,insulin,1ml12$78
Oxycodone Hcl25$62
Terazosin Hcl12$56
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim22$42
Ciprofloxacin Hcl14$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$15$26,54451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 401 urology providers in New Jersey.

Other urology in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →